Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis

Yarman, Emine; Yalin, Gülşah; Dogansen, S.; Canbaz, B.; Tanrikulu, S.; Akyuz, F.

doi:10.1111/jcpt.12412

Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis

Atıf İçin Kopyala

Yarman S., Yalin G. Y., Dogansen S. C., Canbaz B., Tanrikulu S., Akyuz F.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.41, sa.5, ss.559-562, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 41 Sayı: 5
Basım Tarihi: 2016
Doi Numarası: 10.1111/jcpt.12412
Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.559-562
İstanbul Üniversitesi Adresli: Evet

Özet

What is known and objectiveSomatostatin analogs control GH/IGF-1 excess in acromegaly. Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis. We present a patient who showed good response to long-acting octreotide (OCT-LAR) treatment in terms of both acromegaly and ulcerative colitis (UC).